<!DOCTYPE html>
<html lang="en" dir="ltr">

<head>
  <title>IgAN Patient Case - Explore Sarah's Journey</title>
  <meta name="description" content="Explore Sarahâ€™s journey with IgAN, from diagnosis to disease progression. Learn how this autoimmune kidney disease can impact her quality of life">
  {{> ../templates/header }}
  <link href="../styles.bundle.css" rel="stylesheet" type="text/css">
</head>

<body>
  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WZLFQZR3" height="0" width="0"
      style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->
  <main class="wrapper" data-page-id="pat-profile-sarah" data-path-level="2">

    {{> ../templates/nav }}
    {{> ../templates/interstitial }}

    <div class="progress-dots-container"></div>

    {{> ../templates/mestc-score-modal }}

    <img id="scroll-arrow" class="update-path" src="./assets/images/scroll-arrow.svg" alt="Scroll arrow down" />

    <div id="sarah-bio-tray" class="mobile-bio-tray">
      <div id="tray-close">
        <p>Baseline Assessment at Biopsy</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">Sarah, 25</p>

      {{> ../templates/sarah-bio }}

      <div class="extra-section">
        <p class="extra-footnote">*Image used with permission from the Renal Fellow Network, from Gallan A. Kidney Biopsy of the Month. Published July 29, 2019. Available at: Kidney Biopsy of the Month: IgA Nephropathy - Renal Fellow Network/.</p>
        <p class="extra-footnote">ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; HPF, high-power field; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C); PAS, periodic acid-Schiff; RBC, red blood cells; UPCR, urine protein creatinine ratio.</p>
      </div>
    </div>

    <!-- //////////////////// SECTION 1 ///////////////////// -->

    <section id="section-1" class="" data-section-id="1" data-section-name="Sarah Patient Information" data-dot-label="Meet Sarah">

      <div class="two-column">

        <div id="left-bio">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic" alt="">
          
          {{> ../templates/sarah-bio }}
        </div>

        <div class="right-side">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic conditional-render" alt="">
          <p class="name conditional-render">Sarah, 25</p>

          <h1 class="sect-1-header">Sarah is a 25-year-old Japanese American woman and recent law school graduate. She began working at a local, fast-paced law firm 6 months prior to her initial exam.</h1>

          <p class="bold">Sarah has been experiencing dark brown urine for the past 2 days following an upper
            respiratory tract infection. She is currently not menstruating and recalled a similar incident when she was
            a teenager.</p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>No remarkable findings upon physical exam</span></li>
            <li><span class="bullet">&bull;</span><span>Her urinalysis showed &gt;25 RBC/HPF and 2+ protein</span></li>
          </ul>

          <div class="divider"></div>

          <h4 class="purple">Sarah was referred to a nephrologist for subsequent workups:</h4>

          <div class="flex">
            <div class="workup">
              <img class="icon update-path" src="./assets/images/gauge-icon.svg" alt="" />
              <p>UPCR 2.1 g/g (~24-hour urine<br class="desktop-only"> protein excretion of <span class="nowrap">2.1 g/d)</span></p>
            </div>
            <div class="workup">
              <img class="icon update-path" src="./assets/images/kidneys-icon.svg" alt="" />
              <p>Kidney biopsy revealed dominant IgA staining and evidence of mesangial hypercellularity, which
                confirmed Sarah&rsquo;s IgAN diagnosis</p>
            </div>
          </div>

          <p class="direction bold align-center tablet-desktop-only">Click the arrows in the carousel below to explore Sarah&rsquo;s baseline characteristics</p>
        </div>

      </div>
    </section>

    <div class="temp-section mobile-only">
      <p class="direction bold align-center">Swipe in the carousel below to explore Sarah&rsquo;s baseline characteristics</p>
    </div>

    <!-- //////////////////// SECTION 2 ///////////////////// -->

    <section id="section-2" class="" data-section-id="2" data-section-name="Sarah Demographic and Information Carousel" data-dot-label="Baseline<br>Characteristics">

      <div class="owl-carousel">
        <div class="carousel-block" id="sarah-block-1">
          <h3 class="label">Age at Biopsy</h3>
          <h4 class="characteristic">25 years old</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>IgAN is primarily diagnosed in adults 20-40 years of
                age<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Clinical presentation and disease progression can vary based on
                the patient&rsquo;s age at diagnosis<sup>3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Caster DJ, et al. <em>Kidney Int Rep</em>. 2023;8(9):1792-1800.
              <span class="bold">2.</span> Lai KN, et al. <em>Nat Rev Dis Primers</em>. 2016;2:16001. <span
                class="bold">3.</span> Gutierrez E, et al. <em>Nephrol Dial Transplant</em>. 2018;33:472-477.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-2">
          <h3 class="label">Race</h3>
          <h4 class="characteristic">East Asian (Japanese)</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Clinical presentation and progression of IgAN can vary greatly
                depending on ethnicity<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Asian ethnicity is associated with faster disease progression
                and greater burden<sup>1</sup></span></li>
            <ul>
              <li><span class="bullet">&ndash;</span><span>East Asian patients are 4x more likely to develop ESKD</span>
              </li>
            </ul>
          </ul>

          <div class="footnotes">
            <p>ESKD, end-stage kidney disease.</p>
            <p><span class="bold">Reference: 1.</span> Yeo SC, et al. <em>Nephrology (Carlton)</em>. 2019;24(9):885-895.
            </p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-3">
          <h3 class="label">Estimated GFR at Biopsy</h3>
          <h4 class="characteristic">70 mL/min/<br class="mobile-only"/>1.73 m<sup>2</sup></h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Sarah&rsquo;s eGFR at biopsy indicated that she is in Stage 2
                CKD:
                some kidney damage leading to a mild loss of kidney function</span></li>
            <li><span class="bullet">&bull;</span><span>eGFR decline is a validated risk factor of IgAN progression
                and is strongly associated with the risk of CKD progression and mortality<sup>1</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.</p>
            <p><span class="bold">Reference: 1.</span> Coresh J, et al. <em>JAMA</em>. 2014;311(24):2518-2531.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-4">
          <h3 class="label">Blood Pressure at Biopsy</h3>
          <h4 class="characteristic">130/80 mm Hg</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Sarah&rsquo;s blood pressure was slightly elevated at
                biopsy</span></li>
            <li><span class="bullet">&bull;</span><span>Hypertension can be a predictor of IgAN progression at the time
                of diagnosis<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Reduction of hypertension lowers the risk of progression to
                kidney failure<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Maixnerova D, et al. <em>J Nephrol</em>. 2016;29(4):535-541.
              <span class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-5">
          <h3 class="label">Proteinuria at Biopsy</h3>
          <h4 class="characteristic">2.1 g/d</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Sarah had elevated proteinuria at the time of biopsy</span></li>
            <li><span class="bullet">&bull;</span><span>Proteinuria is a validated prognostic marker linked to
                long-term kidney outcomes, including eGFR decline and ESKD<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Proteinuria reduction inversely correlates with serum
                creatinine doubling, ESKD, and death<sup>2,3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.</p>
            <p><span class="bold">References: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276. <span
                class="bold">2.</span> Thompson A, et al. <em>Clin J Am Soc Nephrol</em>. 2019;14(3):469-481. <span
                class="bold">3.</span> Inker L, et al. <em>Am J Kidney Dis</em>. 2016;68(3):392-401.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-6">
          <h3 class="label">ACE<span class="lower">i</span>/ARB Use at the Time of Biopsy</h3>
          <h4 class="characteristic">None</h4>

          <p>While ACEi/ARBs are recommended as part of supportive care, Sarah had not initiated treatment at the time
            of her biopsy.<sup>1</sup></p>

          <div class="footnotes">
            <p>ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p>
            <p><span class="bold">Reference: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-7">
          <h3 class="label">MEST-C Score</h3>
          <h4 class="characteristic">M1 E0 S0 T0 C0</h4>

          <p>Sarah&rsquo;s biopsy was evaluated using the Oxford classification, or MEST-C score. Her biopsy showed
            mesangial hypercellularity in &gt;50% of glomeruli, but was absent of endocapillary hypercellularity,
            segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, and crescents.</p>
          <p>The MEST-C score can serve as a valuable early prognostic tool and should be considered when evaluating the
            risk of progression to ESKD.<sup>1-3</sup></p>

          <div class="button cta modal-trigger" data-trigger-id="mest-c-score">
            <p>Learn more about MEST-C</p>
          </div>

          <div class="footnotes">
            <p>ESKD, end-stage kidney disease; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity
              (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C).</p>
            <p><span class="bold">References: 1.</span> Cattran DC, et al. <em>Kidney Int Rep</em>.
              2023;8(12):2515-2528. <span class="bold">2.</span> Haaskjold YL, et al. <em>BMC Nephrology</em>.
              2022;23:26. <span class="bold">3.</span> Coppo R, et al. <em>Kidney Int</em>. 2014;86(4):828-836.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-8">
          <h3 class="label">Immunosuppression Use at or Prior to Biopsy </h3>
          <h4 class="characteristic">None</h4>

          <p>While the clinical benefits of immunosuppressive therapy have not been established in patients with IgAN,
            they may be used in specific patient populations if the risk/benefit profile is acceptable.<sup>1</sup></p>

          <div class="footnotes">
            <p><span class="bold">Reference: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>
      </div>
    </section>
    
    <div class="temp-section">
      <div class="footnotes">
        <p>*Image used with permission from the Renal Fellow Network, from Gallan A. Kidney Biopsy of the Month. Published July 29, 2019. Available at: <a class="format-url link-color" href="https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/" target="_blank">https://www.renalfellow.org/2019/07/29/kidney-biopsy-of-the-month-iga-nephropathy/</a>.</p>
        <p>ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; HPF, high-power field; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C); PAS, periodic acid-Schiff; RBC, red blood cells; UPCR, urine protein creatinine ratio.</p>
      </div>

      <img class="mobile-only update-path mobile-bio-trigger" data-tray-id="sarah-bio-tray" id="mobile-bio-trigger" src="./assets/images/profiles/mobile-bio-btn.png" alt="Baseline Assessment trigger button"/>
    </div>

    <!-- //////////////////// SECTION 3 ///////////////////// -->

    <section id="section-3" class="gray-bg" data-section-id="3" data-section-name="Sarah's Risk of Progression" data-dot-label="Risk of<br>Progression">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">Sarah&rsquo;s Risk of Progression</h1>
          <p class="desc-text">After Sarah&rsquo;s IgAN diagnosis was confirmed by biopsy, she was prescribed an
            ACEi/ARB. One year later, her proteinuria stabilized to 1 g/d and her blood pressure was lowered to 120/80
            with supportive care and lifestyle modifications.</p>

          <div class="graph-container">
            <div class="hotspot" id="state-1" data-value="Age 27;5%"></div>
            <div class="hotspot" id="state-2" data-value="Age 28;11%"></div>
            <div class="hotspot" id="state-3" data-value="Age 29;18%"></div>
            <div class="hotspot" id="state-4" data-value="Age 30;25%"></div>
            <div class="hotspot" id="state-5" data-value="Age 31;33%"></div>

            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/sarah/progression-graph-state-0.png" id="state-0"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-1.png" id="state-1"
                class="graph visible update-path"
                alt="Graph showing Sarah's risk of progression at age 27. 5 percent risk one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-2.png" id="state-2"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 28. 11 percent risk two years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-3.png" id="state-3"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 29. 18 percent risk three years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-4.png" id="state-4"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 30. 25 percent risk four years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-5.png" id="state-5"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 31. 33 percent risk five years after stabilization on optimized supportive care" />
            </div>

            <div class="mobile-only">
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-0-mobile.png" id="state-0"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-1-mobile.png" id="state-1"
              class="graph mobile-graph visible update-path"
              alt="Graph showing Sarah's risk of progression at age 27. 5 percent risk one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-2-mobile.png" id="state-2"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 28. 11 percent risk two years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-3-mobile.png" id="state-3"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 29. 18 percent risk three years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-4-mobile.png" id="state-4"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 30. 25 percent risk four years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-5-mobile.png" id="state-5"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 31. 33 percent risk five years after stabilization on optimized supportive care" />
            </div>
          </div>

          <a href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults"
          target="_blank" class="button cta" id="sect-3-exit">
          <p>View the International <br class="mobile-only"/>IgAN Prediction Tool</p>
          <img src="./assets/images/external-icon-white.svg" class="update-path" alt="External link icon" />
        </a>

        </div>
      </div>

      <p class="bold">Current KDIGO guidelines do not recommend SGLT2i use in IgAN in the absence of diabetes, as
        additional data are needed to assess efficacy and safety. Treatments in hypothetical patient cases reflect
        current treatment guidelines.<sup>2</sup></p>

      <div class="footnotes">
        <p><sup>a</sup>Predicted risk of progression was calculated using the International IgAN Prediction Tool and
          defined as the risk of a 50% decline in eGFR or ESKD.<sup>1</sup></p>
        <p>ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular
          filtration rate; ESKD, end-stage kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; SGLT2i,
          Sodium-Glucose Transport Protein 2 inhibitor.</p>
        <p><span class="bold">References: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
            class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
      </div>

    </section>

    <!-- //////////////////// SECTION 4 ///////////////////// -->

    <section id="section-4" class="" data-section-id="4" data-section-name="Sarah Impact of Proteinuria" data-dot-label="Impact of<br>Proteinuria">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">Impact of Proteinuria</h1>
          <p class="desc-text">Despite decreasing her proteinuria level by half to 1 g/d,<br class="desktop-only" />
            Sarah remains at risk of progression.</p>
        </div>
      </div>

      <div class="flex">
        <div class="text-side">
          <p class="bold">A retrospective cohort study showed that patients perceived as low risk continue to remain at
            risk of progression to kidney failure within <span class="nowrap">10 years<sup>2</sup></span></p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>30% risk in patients with proteinuria 0.5 to 1 g/d</span></li>
            <li><span class="bullet">&bull;</span><span>~20% risk in patients with proteinuria &lt;0.5 g/d</span></li>
          </ul>
        </div>

        <div class="right-side">
          <p class="bold purple">Use the slider to see how reducing proteinuria below 1 g/d could reduce Sarah&rsquo;s risk of
            progression.</p>
          
          <div class="flex">
            <img src="./assets/images/profiles/sarah/risk-23.png" id="section-4-state-1" class="risk-radial update-path"
              alt="23 percent risk progression at 5 years with proteinuria at 0.5 g/d" />
            <img src="./assets/images/profiles/sarah/risk-28.png" id="section-4-state-2" class="risk-radial update-path"
              alt="28 percent risk progression at 5 years with proteinuria at 0.75 g/d" />
            <img src="./assets/images/profiles/sarah/risk-33.png" id="section-4-state-3"
              class="risk-radial update-path visible" alt="33 percent risk progression at 5 years with proteinuria at 1 g/d" />
    
            <div class="slider-container">
              <div id="state-1-blurb">
                <p>Reducing proteinuria from 1 g/d to 0.5 g/d lowers the risk of progression by ~10%</p>
              </div>
              <div class="">
                <img src="./assets/images/profiles/sarah/section-4-slider-1.svg" id="section-4-state-1"
                  class="slider update-path" alt="Slider shown at 0.5 g/d" />
                <img src="./assets/images/profiles/sarah/section-4-slider-2.svg" id="section-4-state-2"
                  class="slider update-path" alt="Slider shown at 0.75 g/d" />
                <img src="./assets/images/profiles/sarah/section-4-slider-3.svg" id="section-4-state-3"
                  class="slider update-path visible" alt="Slider shown at 1.0 g/d" />
              </div>

              <div class="ff-hotspots hidden">
                <div class="hotspot" id="section-4-state-3" data-value="1.0 g/d"></div>
                <div class="hotspot" id="section-4-state-2" data-value="0.75 g/d"></div>
                <div class="hotspot" id="section-4-state-1" data-value="0.5 g/d"></div>
              </div>
      
              <input type="range" class="range-slider" id="pro-impact" orient="vertical" name="pro-impact" min="1" max="3" value="3" step="1" />
            </div>
          </div>
        </div>
      </div>

      <div class="footnotes">
        <p><sup>a</sup>Predicted risk of progression was calculated using the International IgAN Prediction Tool and
          defined as the risk of a 50% decline in eGFR or ESKD.</p>
        <p>eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.</p>
        <p><span class="bold">References: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
            class="bold">2.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>. 2023;18(6):727-738.</p>
      </div>
    </section>

    <!-- //////////////////// SECTION 5 ///////////////////// -->

    <section id="section-5" class="" data-section-id="5" data-section-name="Sarah Changes in Proteinuria and eGFR Over Time" data-dot-label="Changes in Proteinuria/<br>eGFR Over Time">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">Changes in Proteinuria<br class="desktop-only"/> and eGFR Over Time</h1>
          <p class="desc-text">Through medication and lifestyle changes, Sarah may be able to reduce her proteinuria and slow her eGFR decline.</p>
        </div>
      </div>

      <p class="graphs-header">Changes in proteinuria and eGFR over time</p>
      <p class="direction">Use the slider to see how Sarah&rsquo;s proteinuria and eGFR may change over time</p>

      <img src="./assets/images/profiles/sarah/section-5-key.png" class="update-path key tablet-desktop-only" alt=""/>

      <div class="graphs-container">
        <div class="left-side">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/sarah/pro-over-time-state-1.png" id="section-5-state-1"
              class="update-path graph visible" alt="Graph modeling proteinuria progression over time with and without intervention, starting at biopsy"/>
            <img src="./assets/images/profiles/sarah/pro-over-time-state-2.png" id="section-5-state-2"
              class="update-path graph" alt="Graph showing proteinuria level with and without intervention, after two years"/>
            <img src="./assets/images/profiles/sarah/pro-over-time-state-3.png" id="section-5-state-3"
              class="update-path graph" alt="Graph showing proteinuria progression with and without intervention, at four years"/>
            <img src="./assets/images/profiles/sarah/pro-over-time-state-4.png" id="section-5-state-4"
              class="update-path graph" alt="Graph showing proteinuria with and without intervention, at six years"/>
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-1-mobile.png" id="section-5-state-1"
              class="update-path mobile-graph graph visible" alt="Graph modeling proteinuria progression over time with and without intervention, starting at biopsy"/>
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-2-mobile.png" id="section-5-state-2"
              class="update-path mobile-graph graph" alt="Graph showing proteinuria level with and without intervention, after two years"/>
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-3-mobile.png" id="section-5-state-3"
              class="update-path mobile-graph graph" alt="Graph showing proteinuria progression with and without intervention, at four years"/>
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-4-mobile.png" id="section-5-state-4"
              class="update-path mobile-graph graph" alt="Graph showing proteinuria with and without intervention, at six years"/>
          </div>
        </div>
        <div class="right-side">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-1.png" id="section-5-state-1"
              class="update-path graph visible" alt="Graph modeling eGFR decline over time with and without intervention, starting at biopsy"/>
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-2.png" id="section-5-state-2"
              class="update-path graph" alt="Graph showing eGFR with and without intervention, after two years"/>
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-3.png" id="section-5-state-3"
              class="update-path graph" alt="Graph showing eGFR with and without intervention, after four years"/>
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-4.png" id="section-5-state-4"
              class="update-path graph" alt="Graph showing eGFR with and without intervention, after six years"/>
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-1-mobile.png" id="section-5-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling eGFR decline over time with and without intervention, starting at biopsy"/>
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-2-mobile.png" id="section-5-state-2"
                class="update-path mobile-graph graph" alt="Graph showing eGFR with and without intervention, after two years"/>
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-3-mobile.png" id="section-5-state-3"
                class="update-path mobile-graph graph" alt="Graph showing eGFR with and without intervention, after four years"/>
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-4-mobile.png" id="section-5-state-4"
                class="update-path mobile-graph graph" alt="Graph showing eGFR with and without intervention, after six years"/>
          </div>
        </div>
      </div>

      <div class="slider-container">
        <div class="tablet-desktop-only">
          <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1" class="update-path slider visible" 
            alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2" class="update-path slider"
            alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3" class="update-path slider"
            alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4" class="update-path slider"
            alt="Slider shown at 6 years">
        </div>
        <div class="mobile-only">
          <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-5-state-1"
            class="update-path mobile-graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-5-state-2" class="update-path mobile-graph slider"
            alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-5-state-3" class="update-path mobile-graph slider"
            alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-5-state-4" class="update-path mobile-graph slider"
            alt="Slider shown at 6 years">
        </div>

        <input type="range" class="range-slider" id="changes-over-time" name="changes-over-time" min="1" max="4" value="1" step="1" />
      </div>

      <div class="footnotes">
        <p>Changes in proteinuria and eGFR, as well as the differences between "With intervention" and "Without intervention", are hypothetical and based on trends seen in clinical trials and cohort studies.<sup>1-4</sup></p>
          <p>eGFR, estimated glomerular filtration rate.</p>
        <p><span class="bold">References: 1.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>.
          2023;18(6):727-738. <span class="bold">2.</span> Faucon AL, et al. <em>Nephrol Dial Transplant</em>.
          2024;30:gfae085. <span class="bold">3.</span> Rovin BH, et al. <em>Lancet</em>. 2023;402(10417):2077-2090. <span class="bold">4.</span>
          Lafayette R, et al. <em>Lancet</em>. 2023;402:859-870.</p>
      </div>
    </section>

    <!-- //////////////////// SECTION 6 ///////////////////// -->

    <section id="section-6" class="gray-bg" data-section-id="6" data-section-name="Sarah Impact of eGFR Decline on Progression to ESKD" data-dot-label="Impact of eGFR<br>Decline on<br>Progression">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">Impact of eGFR Decline on<br class="desktop-only"/> Progression to Kidney Failure</h1>
        </div>
      </div>

      <p class="graphs-header">If Sarah&rsquo;s eGFR decline stabilizes, this can delay the onset of kidney failure.</p>
      <p class="direction">Select a button below to see how different rates of eGFR decline can impact progression to
        kidney failure.</p>

      <div class="graph-container">
        <div class="tablet-desktop-only">
          <img src="./assets/images/profiles/sarah/section-6-graph-state-0.png" id="0" class="update-path graph"
            alt="Graph depicting changes in eGFR over time" />
          <img src="./assets/images/profiles/sarah/section-6-graph-state-1.png" id="state-1" class="update-path graph"
            alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
          <img src="./assets/images/profiles/sarah/section-6-graph-state-2.png" id="state-2" class="update-path graph"
            alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
          <img src="./assets/images/profiles/sarah/section-6-graph-state-3.png" id="state-3" class="visible update-path graph"
            alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-0-mobile.png" id="0" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-1-mobile.png" id="state-3" class="visible update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-2-mobile.png" id="state-2" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-3-mobile.png" id="state-1" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
        </div>

        <div class="hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
        <div class="hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
        <div class="hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>

        <div class="upper-hotspots">
          <div class="hotspot lower-hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
          <div class="hotspot lower-hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
          <div class="hotspot lower-hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
        </div>
      </div>

      <div class="footnotes">
        <p>CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.</p>
      </div>
    </section>

    <!-- //////////////////// SECTION 7 ///////////////////// -->

    <section id="section-7" class="gray-bg" data-section-id="7" data-section-name="Sarah Considerable Impact on Physical, Mental, and Emotional Health" data-dot-label="Impact on QoL">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">A Considerable Impact on Physical, Mental, and Emotional Health<sup>1,2</sup></h1>
        </div>
      </div>

      <div class="icon-flex">
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-anxiety.svg" class="update-path" alt="" />
          <p>~25% of patients with IgAN experience anxiety<sup>1,a</sup></p>
        </div>
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-depression.svg" class="update-path" alt="" />
          <p>~30% of patients with IgAN experience depression<sup>2,b</sup></p>
        </div>
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-activity.svg" class="update-path" alt="" />
          <p>~40% daily activity impairment reported<sup>3,c</sup></p>
        </div>
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-work.svg" class="update-path" alt="" />
          <p>Up to 40% overall work impairment reported<sup>3,c</sup></p>
        </div>
      </div>

      <div class="footnotes">
        <p class=""><sup>a</sup>Survey of U.S. patients on coping with IgAN from the NKF Voice of the Patient Report.</p>
        <p class=""><sup>b</sup>Prospective observational study of adult patients with biopsy-confirmed IgAN.</p>
        <p class=""><sup>c</sup>Based on real-world data from the Adelphi IgAN Disease Specific Programme (DSP), a
          point-in-time survey of IgAN-treating nephrologists and their patients in the United
          States, EU5 (France, Germany, Italy, Spain, and the United Kingdom), Japan, and China between June and October
          2021. Data presented are for patients with IgAN in the United States, and are based on the average impairment reported by participants.</p>

        <p><span class="bold">References: 1.</span> The Voice of the Patient. National Kidney Foundation. December 8,
          2020. Accessed June 10, 2024. https://www.igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf. <span
            class="bold">2.</span> Zhao Y, et al. <em>J Int Med Res</em>. 2020;48(1):300060519898008. <span
            class="bold">3.</span> Lafayette R, et al. Poster. International Symposium on IgA Nephropathy; Tokyo, Japan.
          September 28-30, 2023 (poster P-51).</p>
      </div>
    </section>

    <section class="switch-pat-section" id="switch-pat" data-section-name="Switch Patient">
      <h2 class="yellow-header">SELECT ANOTHER HYPOTHETICAL PATIENT</h2>

      <div class="flex">
        <div class="profile nav-el" data-nav-url="progression/carlos" data-exit-url="progression/carlos">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path" alt="" />
          <h3>Carlos</h3>
        </div>
        <div class="profile nav-el" data-nav-url="progression/mark" data-exit-url="progression/mark">
          <img src="./assets/images/profiles/mark-profile.png" class="update-path" alt="" />
          <h3>Mark</h3>
        </div>
      </div>

      <img src="./assets/images/or-line-graphic.png" class="or-line update-path" alt="Or" />

      <div class="button nav-el" id="discover" data-nav-url="pathogenesis/index" data-exit-url="pathogenesis/index">
        <p>Discover the pathogenesis of IgAN</p>
      </div>
    </section>

    {{> ../templates/footer-el }}

  </main>

  <script type="text/javascript" src="../static.bundle.js" charset="utf-8"></script>
</body>

</html>